Company files new drug application for topical ED treatment

October 4, 2007

NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.

NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.

The company said it is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products.